GlassScriptPhysician profile
Eugene Wayne Tsai
NPI 1053301200
$2,062.00
in general payments reported to CMS, 2019-2025
13 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $85.60 · 2021: $200 · 2022: $289 · 2023: $535 · 2024: $364 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $771.89 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $390.18 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $267.89 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $241.60 | 2021-2025 | Dupixent |
| Optinose US, INC. | $109.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.77 | 2025 | |
| Genentech USA, INC. | $64.11 | 2019-2020 | |
| Pfizer INC. | $57.39 | 2022-2024 | |
| Alk-Abello, INC | $23.64 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.92 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.86 | 2021 | |
| Incyte Corporation | $12.73 | 2022 | |
| Leo Pharma INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.